23 July 2024 - Findings from the House Oversight investigation add to criticism that pharmacy-benefit managers are driving up drug spending.
The drug middlemen that promise to control costs have instead steered patients toward higher-priced medicines and affiliated pharmacies—steps that increase spending and reduce patient choice, a House investigation found.